Evelo Biosciences (NASDAQ:EVLO) is up 25% premarket on the heels of the announcement
that EDP1815 will be included in the TACTIC-E clinical trial,
evaluating the safety and efficacy of certain experimental therapies to
prevent and treat complications of COVID-19.
Phase 2/3 TACTIC-E trial will evaluate up to 469
patients per arm at Addenbrooke’s Hospital and other leading UK clinical
centres.
EDP1815 has been observed to have favorable tolerability and anti-inflammatory activity in a Phase 1b trial for psoriasis.
The primary outcome measure is a reduction in the
number of patients who develop severe complications of organ failure,
ventilation, or death.
Secondary outcomes include duration of stay in hospital, duration of oxygen therapy and time to clinical improvement.
Interim data are anticipated in Q4.
Additionally, if the COVID-19 trial is successful,
the Company plans to investigate EDP1815 as a potential therapy for
other diseases, such as influenza, in which cytokine storm and
hyperinflammation play a role.
https://seekingalpha.com/news/3584802-evelo-bios-edp1815-to-advance-mid-stage-tactic-e-covidminus-19-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.